CD4 + tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts
Authors:
- Anaïs Jiménez-ReinosoAJAnaïs Jiménez-Reinoso
- Magdalena Molero-AbrahamMMMagdalena Molero-Abraham
- Cristina CirauquiCCCristina Cirauqui
- Belén BlancoBBBelén Blanco
- Eva M. Garrido-MartinEGEva M. Garrido-Martin
- Daniel Nehme-ÁlvarezDNDaniel Nehme-Álvarez
- Carmen Domínguez-AlonsoCDCarmen Domínguez-Alonso
- Ángel Ramírez-FernándezÁRÁngel Ramírez-Fernández
- Laura Díez-AlonsoLDLaura Díez-Alonso
- Ángel Nuñez-BuizaÁNÁngel Nuñez-Buiza
- África González-MurilloÁGÁfrica González-Murillo
- Raquel TobesRTRaquel Tobes
Preprint
Abstract
Adoptive transfer of tumor-infiltrating lymphocytes (TIL) has shown remarkable results in melanoma, but only modest clinical benefit in other cancers, even after TIL have been genetically modified to improve their tumor homing, cytotoxic potential or overcoming cell exhaustion. The required ex vivo TIL expansion process may induce changes in the T cell clonal composition, which could likely compromise the tumor reactivity of TIL preparations and ultimately the success of TIL therapy. A promising approach based on the production of bispecific T cell engagers (TCE) by engineered T cells (STAb-T therapy) improves the efficacy of current T cell redirection strategies against tumor-associated antigens in hematological tumors. We studied the TCRβ repertoire in non-small cell lung cancer (NSCLC) tumors and in ex vivo expanded TIL from two unrelated patients. We generated TIL secreting anti-epidermal growth factor receptor (EGFR) x anti-CD3 TCE (TIL STAb ) and tested their antitumor efficacy in vitro and in vivo using a NSCLC patient-derived xenograft (PDX) model in which tumor fragments and TIL from the same patient were transplanted into hIL-2 NOG mice. We confirmed that the standard TIL expansion protocol promotes the loss of tumor-dominant T cell clones and the overgrowth of virus-reactive TCR clonotypes that were marginally detectable in primary tumors. We demonstrated the antitumor activity of TIL STAb both in vitro and in vivo when administered intratumorally and systemically in an autologous immune-humanized PDX EGFR + NSCLC mouse model, where tumor regression was mediated by TCE-redirected CD4 + TIL bearing non-tumor dominant clonotypes. SIGNIFICANCE: Epithelial tumor-derived TIL can be engineered to secrete TCE capable of redirecting T cells bearing non-tumor-dominant clonotypes regardless of their phenotype, which could have broad applications in immunotherapy for solid tumors.Keywords
All Related Versions
- Published version: OncoImmunology, 13 (1), 2392897.
This publication has 36 references indexed in Scilit:
- Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discoveryImmunity, 2021
- T cell receptor repertoires of ex vivo–expanded tumor-infiltrating lymphocytes from breast cancer patientsImmunologic Research, 2020
- Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerCell, 2020
- Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T CellsCancer Cell, 2019
- FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effectiveLung Cancer, 2019
- Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapyNature Communications, 2019
- Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignanciesCancer Immunology, Immunotherapy, 2018
- Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse modelNature Communications, 2017
- T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapyLaboratory Investigation, 2017
- Non-small-cell lung cancers: a heterogeneous set of diseasesNature Reviews Cancer, 2014